SG11202001068YA - Compositions and methods for treatment of atopic dermatitis and treatment selection - Google Patents

Compositions and methods for treatment of atopic dermatitis and treatment selection

Info

Publication number
SG11202001068YA
SG11202001068YA SG11202001068YA SG11202001068YA SG11202001068YA SG 11202001068Y A SG11202001068Y A SG 11202001068YA SG 11202001068Y A SG11202001068Y A SG 11202001068YA SG 11202001068Y A SG11202001068Y A SG 11202001068YA SG 11202001068Y A SG11202001068Y A SG 11202001068YA
Authority
SG
Singapore
Prior art keywords
treatment
compositions
methods
atopic dermatitis
selection
Prior art date
Application number
SG11202001068YA
Inventor
Michael D Howell
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11202001068YA publication Critical patent/SG11202001068YA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/5743Specifically defined cancers of skin, e.g. melanoma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/20Dermatological disorders
    • G01N2800/202Dermatitis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202001068YA 2017-08-16 2018-08-15 Compositions and methods for treatment of atopic dermatitis and treatment selection SG11202001068YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762546210P 2017-08-16 2017-08-16
PCT/IB2018/056131 WO2019035005A1 (en) 2017-08-16 2018-08-15 Compositions and methods for treatment of atopic dermatitis and treatment selection

Publications (1)

Publication Number Publication Date
SG11202001068YA true SG11202001068YA (en) 2020-03-30

Family

ID=63686016

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001068YA SG11202001068YA (en) 2017-08-16 2018-08-15 Compositions and methods for treatment of atopic dermatitis and treatment selection

Country Status (12)

Country Link
US (1) US20210148910A1 (en)
EP (1) EP3669004A1 (en)
JP (1) JP2020531439A (en)
KR (1) KR20200040803A (en)
CN (1) CN110997939A (en)
AU (1) AU2018318435A1 (en)
CA (1) CA3071783A1 (en)
EA (1) EA202090427A1 (en)
IL (1) IL272646A (en)
MA (1) MA51647A (en)
SG (1) SG11202001068YA (en)
WO (1) WO2019035005A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
TW202229339A (en) * 2020-12-03 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 Antibody binding to thymic stromal lymphopoietin and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
SE462454B (en) 1988-11-10 1990-06-25 Pharmacia Ab METHOD FOR USE IN BIOSENSORS
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU4025300A (en) 1999-03-24 2000-10-09 Packard Bioscience Company Continuous porous matrix arrays
CA2382545C (en) 1999-08-27 2013-08-13 Phylos, Inc. Methods for encoding and sorting in vitro translated proteins
CA2469403C (en) 2001-12-05 2015-06-02 Jonathan Mark Boutell Protein arrays for allelic variants and uses thereof
CN103278641A (en) * 2005-10-21 2013-09-04 株式会社芳珂 Atopic dermatitis marker and technique of using the same
EP1981912A2 (en) * 2006-01-13 2008-10-22 Irm, Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2773774A4 (en) * 2011-11-03 2015-06-10 Merck Sharp & Dohme Biomarkers for tslp treatment
US9790506B2 (en) * 2013-10-02 2017-10-17 The Regents Of The University Of California Diagnostic and screening methods for atopic dermatitis

Also Published As

Publication number Publication date
CN110997939A (en) 2020-04-10
AU2018318435A1 (en) 2020-04-02
WO2019035005A1 (en) 2019-02-21
EA202090427A1 (en) 2020-06-08
JP2020531439A (en) 2020-11-05
CA3071783A1 (en) 2019-02-21
EP3669004A1 (en) 2020-06-24
KR20200040803A (en) 2020-04-20
US20210148910A1 (en) 2021-05-20
MA51647A (en) 2020-06-24
IL272646A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
IL251066A0 (en) Compositions and methods of use for treating metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
EP3474879A4 (en) Compositions and methods of treating melanoma
EP3341392A4 (en) Compositions and methods for treatment of pain
IL265473B1 (en) Uses of il-13 antagonists for treating atopic dermatitis
IL272949A (en) Improved treatment of atopic dermatitis with tradipitant
HK1247789A1 (en) Compositions and methods for treatment of edema
HK1257853A1 (en) Compositions and methods for the treatment and prevention of radiation dermatitis
ZA201806503B (en) Treatment of canine atopic dermatitis
HK1250145A1 (en) Compositions and methods of treating multiple myeloma
IL272646A (en) Compositions and methods for treatment of atopic dermatitis and treatment selection
HK1254242A1 (en) Composition for treatment of inflammatory bowel disease and atopic dermatitis
GB201511799D0 (en) Composition and methods of treatment
GB201621737D0 (en) Compositions and methods of treatment
IL273850A (en) Compositions and methods for treatment of fibrosis
EP3247364A4 (en) Compositions and methods of treating microbes
IL248846A0 (en) Methods and compositions of dasotraline for treatment of adhd
GB201605127D0 (en) Composition and methods of treatment
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
ZA201903005B (en) Methods and compositions for treating atopic dermatitis
EP3294417A4 (en) Compositions and methods for treatment of glioma
EP3280406A4 (en) Compositions and methods for treatment of movement disorders
IL271778A (en) Methods of treating atopic dermatitis
GB201710491D0 (en) Composition and methods of treatment
AU2015903210A0 (en) Compositions and methods of treatment